Solid Biosciences
SLDB
80 hedge funds and large institutions have $213M invested in Solid Biosciences in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 6 closing their positions.
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
45% more funds holding
Funds holding: 55 → 80 (+25)
5.29% more ownership
Funds ownership: 92.66% → 97.96% (+5.3%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less capital invested
Capital invested by funds: $466M → $213M (-$253M)
61% less call options, than puts
Call options by funds: $51K | Put options by funds: $131K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$14.6M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$10.9M |
| 3 |
BlackRock
New York
|
+$10.5M |
| 4 |
Millennium Management
New York
|
+$8.91M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$9.45M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$7.63M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.24M |
| 4 |
DM
Deerfield Management
New York
|
-$4.63M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.14M |
SLDB Hedge Fund Activity: Q2 2024 in Review
80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2024, worth a combined $213M — down 54% from $466M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SLDB positions and 6 closed out — a net gain of 25 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $14.6M. The largest seller was Janus Henderson Group, cutting an estimated $9.45M.
- 80 institutional investors held Solid Biosciences (SLDB) as of Q2 2024, up from 55 in Q1 2024.
- Funds reported $213M of Solid Biosciences stock for Q2 2024, down 54% quarter-over-quarter.
- 31 funds opened new Solid Biosciences positions in Q2 2024 and 6 closed out, a net change of +25 holders.
- The largest Solid Biosciences buyer in Q2 2024 was Vestal Point Capital, an estimated $14.6M added.
- The largest Solid Biosciences seller in Q2 2024 was Janus Henderson Group, an estimated $9.45M sold.
Based on aggregated 13F filings for Q2 2024.